跳转至内容
Merck
CN

SML3017

甲磺酸乐伐替尼

≥98% (HPLC), TK inhibitor, powder

别名:

4-[3-氯-4-(N’-环丙基脲)苯氧基]-7-甲氧喹啉-6-甲酰胺甲磺酸盐, 4-[3-氯-4-[(环丙基羰基)氨基]苯氧基]-7-甲氧基-6-喹啉甲酰胺甲磺酸盐, 4-[3-氯-4-[[(环丙胺)羰基]氨基]苯氧基]-7-甲氧基-6-喹啉甲酰胺甲基磺酸盐(1:1), E 7080甲磺酸盐, E-7080甲磺酸盐, E7080甲磺酸盐, ER-203492-00甲磺酸盐, 乐伐替尼甲基磺酸盐

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C21H19ClN4O4 · CH4O3S
化学文摘社编号:
857890-39-2
分子量:
522.96
MDL编号:
MFCD18633219
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

甲磺酸乐伐替尼, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

O=C(C1=CC2=C(OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)C=CN=C2C=C1OC)N.O=S(O)(C)=O

InChI

1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

InChI key

HWLFIUUAYLEFCT-UHFFFAOYSA-N

相关类别

生化/生理作用

Lenvatinib (E7080)是一种针对多种受体酪氨酸激酶的口服活性抑制剂，包括VEGFR (Flt-1/KDR/Flt-4 IC50 = 22/4.0/5.2 nM)、PDGFR1/2 (IC50 = 39/51 nM)、FGFR1和KIT (IC50分别= 46和100 nM)，可抑制体外血管生成（VEGF/ scf诱导HUVEC管形成IC50 = 5.1/5.2 nM）。口服Lenvatinib可导致产生scf的人小细胞肺癌H146细胞的小鼠体内肿瘤生长停滞(30 mg/kg b.i.p.o)甚至退化(100 mg/kg b.i.p.o)。
口服活性受体酪氨酸激酶抑制剂(Flt-1/KDR/Flt-4)， PDGFR1/2, FGFR1和KIT具有抗血管生成的体外和体内疗效。

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361d,H373

危险分类

Repr. 2 - STOT RE 2

靶器官

Gastro-intestinal system,Kidney,Bone,Reproductive organs,Adrenal gland

储存分类代码

11 - Combustible Solids

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000238353
0000221887
0000221889
0000220386
0000221887

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Reina Sasaki et al.
International journal of molecular sciences, 21(9) (2020-05-14)
Multiple kinase inhibitors are available for patients with advanced hepatocellular carcinoma (HCC). It is largely unknown whether regorafenib or lenvatinib modulates innate immunity including Toll-like receptor (TLR)-signaling pathways in HCC. We performed real-time RT-PCR to investigate 84 TLR-associated gene expression
Mariko Aoyama et al.
Oncology reports, 44(4), 1709-1716 (2020-09-19)
Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using
Haijing Deng et al.
Liver cancer, 9(3), 338-357 (2020-07-11)
Combining anti-angiogenic therapy with immune checkpoint blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for hepatocellular carcinoma (HCC). Tyrosine kinase inhibitors are well-known anti-angiogenic agents and offer potential for combination with anti-PD-1 antibodies. This study investigated the
Junji Matsui et al.
International journal of cancer, 122(3), 664-671 (2007-10-19)
E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. In this study, we show the inhibitory activity of E7080 against SCF-induced angiogenesis in vitro and tumor growth of SCF-producing human small cell
Junji Matsui et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(17), 5459-5465 (2008-09-04)
Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels. However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持